In a 68-year-old male who is 6 ft 1.5 in tall, weighs 268 lb, has had a total hip replacement, resolved atrial fibrillation after two cardiac ablations with a Watchman left atrial appendage closure device, which glucagon‑like peptide‑1 (GLP‑1) receptor agonist or GLP‑1‑based combination would be most appropriate for weight loss?

GLP-1 Therapy for Post-Hip Replacement Weight Loss in a Patient with Resolved Atrial Fibrillation

Semaglutide 2.4 mg subcutaneously once weekly is the optimal choice for this patient, offering superior weight loss efficacy (14.9% mean weight reduction at 68 weeks), once-weekly convenience, and a 46% reduction in atrial fibrillation recurrence risk after cardiac ablation. 1, 2

Why Semaglutide Over Other GLP-1 Receptor Agonists

• Semaglutide achieves 64.9% of patients reaching ≥10% total body weight loss at 68 weeks versus only 2.4% with placebo, making it substantially more effective than liraglutide (5.2-8.0% mean weight loss at 56 weeks). 1

• The once-weekly subcutaneous dosing of semaglutide is more convenient than daily liraglutide injections, which improves long-term adherence—critical for this patient concerned about weight regain. 1

• Semaglutide specifically reduces AF recurrence by 48% (hazard ratio 0.52,95% CI 0.34-0.78) in obese patients post-ablation, with 80.2% freedom from recurrence at 18 months versus 65.2% in controls. 2

Addressing the Patient's Concern About Weight Regain

• Lifelong treatment is necessary because patients regain 50-67% of lost weight within 1 year after GLP-1 cessation, and weight regain of 11.6% occurred after 52 weeks post-discontinuation in STEP trials. 1

• The patient must understand that semaglutide is not a temporary intervention but a chronic disease management strategy, similar to his previous cardiac medications. 1

• Combining semaglutide with structured lifestyle modifications—specifically a 500-kcal daily deficit and minimum 150 minutes weekly of moderate physical activity—maximizes weight maintenance and reduces hip joint stress. 1, 3

Why Not GLP-1 Combination Agents (Dual or Triple Agonists)

• Current evidence shows no significant between-subgroup differences in AF risk reduction when comparing single-receptor GLP-1 agonists versus dual- or triple-receptor co-agonists (Risk Ratio 0.82,95% CI 0.70-0.96 for all GLP-1-based therapies). 4

• Semaglutide monotherapy has the most robust evidence base for both weight loss and AF prevention in this specific clinical context, whereas combination agents lack dedicated trials in post-ablation populations. 1, 2, 4

• The magnitude of weight reduction does not significantly modify AF risk reduction in meta-regression analyses, suggesting semaglutide's antiarrhythmic effects operate partly independently of weight loss through anti-inflammatory and metabolic mechanisms. 4

Cardiovascular Safety in This Patient's Context

• GLP-1 receptor agonists reduce major adverse cardiovascular events by 26% (hazard ratio 0.74,95% CI 0.58-0.95) in patients with type 2 diabetes and established cardiovascular disease, and this patient's history of atrial fibrillation qualifies as cardiovascular disease. 3

• Meta-analyses of seven cardiovascular outcome trials demonstrate 12% reduction in 3-point MACE, 12% reduction in CV death, and 16% reduction in fatal/non-fatal stroke with GLP-1 receptor agonists. 5

• The Watchman device does not contraindicate GLP-1 therapy, and semaglutide's cardioprotective effects—including improved myocardial substrate utilization and anti-inflammatory actions—complement the patient's existing cardiac interventions. 3

Practical Titration and Monitoring Protocol

• Start semaglutide at 0.25 mg subcutaneously once weekly for weeks 1-4, then 0.5 mg for weeks 5-8,1.0 mg for weeks 9-12,1.7 mg for weeks 13-16, and 2.4 mg (maintenance) from week 17 onward. 1

• Evaluate efficacy at 12-16 weeks on maximum tolerated dose, monitoring for signs of dehydration or pancreatitis throughout treatment. 1

• Monitor blood pressure closely as semaglutide produces blood-pressure-lowering effects that may require antihypertensive medication adjustment, particularly important given this patient's cardiac history. 3

Pre-Treatment Screening Requirements

• Confirm absence of personal or family history of medullary thyroid carcinoma (MTC) and multiple endocrine neoplasia syndrome type 2 (MEN2) before prescribing, as these are absolute contraindications. 1, 6

• History of pancreatitis is a relative contraindication requiring heightened monitoring for abdominal pain, nausea, or elevated lipase during treatment. 1

Essential Lifestyle Integration for Hip Joint Protection

• Prescribe resistance training to preserve lean body mass and prevent muscle loss during rapid weight reduction, which is critical for maintaining hip joint stability post-replacement. 1

• Begin with short 10-15 minute exercise sessions and progress gradually each week as tolerance improves, avoiding excessive joint stress while building cardiovascular fitness. 3

• The anticipated 15% weight loss will directly reduce mechanical load on the hip prosthesis, improving long-term joint survival and reducing pain. 3

Common Pitfalls to Avoid

• Do not discontinue semaglutide if the patient experiences mild gastrointestinal side effects during titration—these typically resolve within 4-8 weeks and can be managed by slowing dose escalation. 1

• Do not assume weight loss alone explains semaglutide's AF benefits—the drug exerts direct antiarrhythmic effects through metabolic inflammation reduction independent of weight change. 4

• Do not overlook the need for re-evaluation at 8-12 weeks—lack of weight loss progression or worsening symptoms should prompt reassessment rather than premature discontinuation. 3